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Abstract: The introduction of therapeutic antibodies against tumor necrosis factor (TNF) 
had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are 
powerful agents that are used for remission induction and maintenance therapy in UC and have 
an acceptable safety profile. However, a proportion of UC patients for whom therapy with anti-
TNF agents is indicated fail or become intolerant to treatment with infliximab or adalimumab. 
Hence, there remains an unmet need for novel anti-TNF agents. Golimumab (Simponi®), 
a human anti-TNF antibody that is administered by monthly subcutaneous injections, is the 
most recently introduced TNF blocker for the treatment of UC. Here, we will discuss recent 
literature on clinical efficacy and safety of golimumab induction and maintenance treatment in 
patients with UC. Furthermore, we will discuss the positioning of golimumab for UC in current 
treatment algorithms.
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Introduction
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized 
by mucosal ulceration, leading to symptoms of bloody diarrhea and abdominal pain. 
Although the underlying mechanism of inflammation in UC is incompletely under-
stood, preclinical and clinical studies demonstrated that tumor necrosis factor (TNF) 
plays an important role in the pathogenesis of UC.1 Various therapeutic antibodies that 
target TNF are used in the field of gastroenterology, rheumatology, and dermatology. 
Anti-TNF agents have drastically changed the therapeutic arsenal for UC. Infliximab 
and adalimumab were the first anti-TNF agents that were successfully approved for 
induction and maintenance of remission in UC.2–4 Golimumab (Simponi®, Janssen 
Biotech, Inc., Horsham, PA, USA) is a novel anti-TNF antibody that represents a new 
treatment option for patients suffering from moderate to severe UC failing conventional 
treatment. Administration is by 4-weekly subcutaneous injection. Golimumab was 
approved for the treatment of UC by the US Food and Drug Administration (FDA) in 
May 2013. More recently, in October 2013, the European Medicines Agency (EMA) 
approved golimumab for the treatment of patients with active UC who have an inad-
equate response to conventional therapy or intolerance for such therapies. Here, we 
will give an overview of the available literature about golimumab treatment for UC.
Conventional anti-TNF agents for UC
Infliximab (a chimeric anti-TNF antibody that is administered intravenously) and 
adalimumab (a fully human antibody against TNF that is administered subcutaneously) 
Clinical and Experimental Gastroenterology 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
54
Löwenberg et al
have significantly improved the treatment armamentarium 
for patients with UC. Infliximab and adalimumab are 
powerful agents that are used for remission induction and 
maintenance treatment in patients suffering from moderate 
to severe UC (Table 1).2–4 Infliximab and adalimumab are 
generally safe and well tolerated. Unfortunately, a signifi-
cant proportion of UC patients do not respond to induction 
therapy (primary nonresponders) or require dose escalation 
due to loss of response over time (secondary nonresponders).5 
 Optimization of the dosing regimen by either increasing the 
dose or shortening the treatment interval can be efficacious 
to overcome resistance to these drugs. Coadministration of 
an immunosuppressive drug (such as thiopurines) can be 
efficacious to overcome resistance to these agents, especially 
when antibodies against the given biological have developed. 
If this strategy in secondary nonresponders is unsuccessful, 
or if adverse events require discontinuation of infliximab 
or adalimumab, switching to another anti-TNF agent is 
generally recommended. Hence, there remains an unmet need 
for novel anti-TNF agents for UC patients in whom therapy 
with anti-TNF agents is indicated but who fail or become 
intolerant to infliximab or adalimumab.
Novel anti-TNF agent: golimumab
Golimumab is the latest addition to the anti-TNF treatment 
regimen and is different from other available anti-TNF 
 antibodies with regard to affinity for TNF and protein sta-
bility (Table 1). Golimumab is a transgenic fully human 
monoclonal immunoglobulin G1 antibody that targets a 
unique epitope on the TNF molecule. It was originally syn-
thesized from TNF-immunized transgenic mice expressing 
human immunoglobulin G.6,7 Preclinical work showed that 
the affinity of golimumab for soluble and transmembrane 
TNF and its ability to neutralize TNF is superior to both 
infliximab and adalimumab.8 This work also demonstrated 
that golimumab is superior in terms of its conformational 
stability and its ability to inhibit TNF-induced cytotoxicity 
and human endothelial cell activation compared with 
infliximab and adalimumab. Moreover, treatment with 
golimumab resulted in potent clinical, biochemical, and 
histological anti-inflammatory effects employing a murine 
model of TNF-mediated arthritis.8  Treatment with 1 mg/kg 
golimumab significantly delayed disease progression in this 
particular model, whereas infliximab was effective only at 
10 mg/kg.
Golimumab for rheumatologic 
diseases
Golimumab has been approved by the FDA and EMA for the 
treatment of various chronic immune-mediated inflammatory 
disorders in which TNF plays an important role, including 
rheumatoid arthritis, psoriatic arthritis, and ankylosing 
spondylitis. The first report that described efficacy and safety 
of golimumab in humans was a dose-ranging study in patients 
with rheumatoid arthritis.9 It was shown that treatment with 
golimumab in combination with methotrexate was able 
to reduce disease activity in rheumatoid arthritis patients. 
Besides data on efficacy, this small study also demonstrated 
that golimumab was well tolerated. Pharmacokinetic analysis 
showed consistent (detectable) serum drug concentrations 
after either subcutaneous or intravenous administration 
of golimumab in patients with rheumatoid arthritis.10 
 Subsequently, safety and efficacy of golimumab treatment 
were assessed in methotrexate-naive patients suffering from 
active rheumatoid arthritis. Subcutaneously administered 
golimumab (with or without methotrexate) effectively 
reduced clinical signs of active rheumatoid arthritis, although 
the primary end point (the so-called American College of 
Rheumatology 50 scale, which is used to measure change in 
rheumatoid arthritis symptoms) was not reached.11
A Phase III trial examined efficacy and safety of goli-
mumab in patients with active rheumatoid arthritis despite 
treatment with methotrexate.12 This study showed that the 
addition of golimumab to methotrexate resulted in a sig-
nificant reduction of clinical signs and improved physical 
function in these patients. Another trial demonstrated efficacy 
of golimumab treatment in patients with active rheumatoid 
arthritis who had previously received one or more anti-TNF 
agents.13 A total of 58% of patients had discontinued previ-
ous treatment with anti-TNF antibodies because of lack of 
efficacy, and 53% of them stopped earlier treatment with 
anti-TNF therapy due to other reasons, such as intolerance 
to these drugs. Hence, this work suggested that switching 
rheumatoid arthritis patients from a TNF inhibitor to goli-
mumab might be an effective and safe therapeutic strategy. 
Table 1 The dosing interval of antitumor necrosis factor (TNF) 
agents is determined by several factors, such as half-life, affinity 
for TNF, and protein stability
Anti-TNF Administration  
route
Dosing  
interval
Half-life 
(days)
Infliximab intravenous Every 8 weeks 8–9.5
Adalimumab Subcutaneous Every 2 weeks 14
Golimumab Subcutaneous Every 4 weeks 14
Notes: Golimumab is a stable human monoclonal antibody that can bind with 
high affinity to TNF, enabling less frequent dosing compared with adalimumab. 
An advantage of golimumab over infliximab is the fact that it is administered 
subcutaneously.
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Moreover, golimumab proved to be effective and well tol-
erated in patients with ankylosing spondylitis and psoriatic 
arthritis.14,15
So far, clinical studies have shown that golimumab 
is an effective and safe therapeutic option for various 
 rheumatologic diseases, including rheumatoid arthritis, 
psoriatic arthritis, and ankylosing spondylitis.
Golimumab in UC: efficacy  
and safety data
Golimumab was approved in 2013 by the FDA and EMA for 
the treatment of adult patients with moderately to severely 
active UC. The Program of Ulcerative Colitis Research 
Studies Utilizing an Investigational Treatment (PURSUIT) 
clinical studies were the pivotal trials that led to regula-
tory approval of golimumab for UC.16,17 The PURSUIT-SC 
induction study and PURSUIT-Maintenance withdrawal 
trial evaluated anti-TNF-naive patients with moderately 
to severely active UC (defined by a Mayo Clinic score18 
of 6–12 points with an endoscopy subscore of $2) who 
demonstrated  corticosteroid dependence or who had an 
inadequate response to or failed to tolerate at least one of the 
following drugs: oral 5- aminosalicylate acid, oral corticoster-
oids, or a thiopurine (azathioprine or mercaptopurine). Safety 
and efficacy of golimumab induction therapy was studied in 
the randomized, double-blind, placebo-controlled PURSUIT-
SC study, which consisted of a Phase II dose-ranging study 
and a Phase III trial.17 Patients were randomized to receive 
subcutaneous administration with 400 mg and 200 mg or 200 
mg and 100 mg golimumab at weeks 0 and 2, respectively, 
or placebo. The primary end point of the induction study 
was the proportion of patients who had a clinical response 
at week 6, defined by a decrease in the Mayo Clinic score 
of at least 30% and at least three points from baseline, 
with either a decrease in the rectal bleeding subscore of at 
least one point from baseline or a rectal bleeding subscore 
of 0 or 1. This end point was met by 51.0% and 54.9% of 
patients receiving golimumab 200/100 mg or 400/200 mg, 
respectively, and 30.3% of patients in the placebo arm 
(P,0.0001 for both comparisons versus placebo). Patients 
who received treatment with golimumab exhibited a clinical 
response as early as week 2. This trial also met its secondary 
endpoints, including clinical remission (defined as a Mayo 
Clinic score #2 with no individual subscore .1), mucosal 
healing (ie, Mayo Clinic endoscopic subscore of 0 or 1), 
and change from baseline in Inflammatory Bowel Disease 
Questionnaire score, all assessed at week 6. The proportion 
of patients who achieved clinical remission at week 6 was 
17.8% in the 200/100 mg golimumab group, 17.9% in the 
400/200 mg golimumab group, and 6.4% in the placebo 
group (P,0.0001 for both comparisons versus placebo). 
Mucosal healing rates at week 6 were 45.1%, 42.3%, and 
28.7% in patients who received 400/200 mg golimumab, 
200/100 golimumab, or placebo, respectively (differences 
were statistically significant for both dosing regimens com-
pared with placebo). Finally, the mean change from baseline 
in Inflammatory Bowel Disease Questionnaire19 scores at 
week 6 was 14.8 points in the placebo arm versus 27.0 points 
and 26.9 points in the 200/100 mg and 400/200 mg goli-
mumab groups, respectively (P,0.0001 for both golimumab 
groups versus placebo). Based on the outcomes of the 
 PURSUIT-SC induction study, it was concluded that induc-
tion treatment with golimumab is effective and safe for 
patients with moderate to severe active UC. Pharmacokinetic 
analysis showed consistent (detectable) dose-proportional 
golimumab serum concentrations after subcutaneous and 
intravenous administration in UC patients.17
In addition, a placebo-controlled Phase III maintenance 
trial was completed that evaluated safety and efficacy of sub-
cutaneous golimumab maintenance treatment in patients with 
moderately to severely active UC.16 Patients who achieved a 
clinical response with golimumab induction therapy were sub-
sequently randomized to treatment with 50 mg or 100 mg goli-
mumab every 4 weeks or placebo, with a 54-week follow-up. 
The complex study design consisted of monthly assessments 
in order to ensure clinical response using the partial Mayo 
Clinic score and the full Mayo Clinic score (including the 
endoscopic subscore) at week 30 and week 54. Patients who 
did not respond to golimumab induction treatment received 
open-label treatment with 100 mg golimumab at 4-week treat-
ment intervals. It was shown that treatment with golimumab 
was able to maintain clinical responses through week 54 
(primary end point: continuous clinical response among goli-
mumab induction responders through week 54) in 47.0% and 
49.7% of patients who received 50 mg or 100 mg golimumab 
every 4 weeks, respectively, versus 31.2% in the placebo 
group (P=0.010 and P,0.001, respectively). Clinical remis-
sion and mucosal healing at week 30 and week 54 (secondary 
end points) among golimumab induction responders were 
seen in a significantly higher percentage of patients receiving 
active treatment with 50 mg and 100 mg golimumab versus 
placebo. Clinical remission at week 30 and week 54 was 
15.6%, 23.2%, and 27.8% in the placebo, golimumab 50 mg, 
and golimumab 100 mg groups, respectively (P=0.122 and 
P=0.004 for 50 mg and 100 mg golimumab-treated patients 
versus placebo). Based on these outcomes, the FDA advised 
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golimumab maintenance therapy every 4 weeks at a dose 
of 100 mg.
Furthermore, mucosal healing rates at weeks 30 and 54 
were seen in 26.6%, 41.7%, and 42.4% of patients receiving 
placebo, 50 mg golimumab, or 100 mg golimumab, respec-
tively (differences between placebo and the two golimumab 
doses reached statistical significance: P,0.05). With regard 
to safety, the percentages of (serious) adverse events for 
all patients were not significantly different among subjects 
receiving placebo, 50 mg, or 100 mg golimumab, except for 
injection site reactions, which were seen in 7.1% of patients 
receiving 100 mg golimumab in the PURSUIT-Maintenance 
trial versus 1.9% in the 50 mg golimumab group and 1.9% in 
the placebo group. Hence, the PURSUIT-Maintenance trial 
revealed an attractive safety profile of golimumab, which 
seems to be consistent with the other two anti-TNF agents 
(infliximab and adalimumab) that are available for the treat-
ment of UC. The results from the PURSUIT trials are shown 
in Tables 2 and 3.
Optimization of golimumab  
therapy in UC
Therapeutic efficacy of infliximab can be improved in UC 
patients by combining infliximab treatment with a thiopu-
rine. The UC SUCCESS trial revealed that combination 
treatment with infliximab and azathioprine in UC patients 
resulted in higher remission rates compared with infliximab 
or azathioprine monotherapy.20 Steroid-free remission at 
week 16 (primary end point) was seen in 40%, 22%, and 
24% in the infliximab–azathioprine combination group, the 
infliximab monotherapy group, and the azathioprine mono-
therapy group, respectively (P,0.05 compared with inflix-
imab; P,0.05 compared with  azathioprine). However, the 
follow-up period of 16 weeks was relatively short, as the 
optimal effect of thiopurines can be observed only after 
2–4 months of therapy. If therapeutic drug monitoring 
would have been performed, the benefit of both azathioprine 
and infliximab would probably become more pronounced. 
Of note, this trial was discontinued prematurely due to 
slow patient recruitment. Whether efficacy outcomes can 
also be improved in UC patients receiving treatment with 
golimumab combined with an immunomodulator needs to 
be further explored.
Evidence suggests that there is an association between 
infliximab trough levels (eg, serum drug level measured 
just before the next administration) and clinical outcomes 
in UC patients. It has been demonstrated that detectable 
infliximab trough levels are associated with endoscopic 
improvement and a lower colectomy risk in UC patients.21 
On the other hand, this work showed that undetectable trough 
levels, irrespective of antidrug antibody levels, are associ-
ated with less favorable clinical outcomes. Whether this also 
holds true for golimumab needs additional investigation. 
Noteworthy is that higher serum golimumab concentrations 
have been associated with improved clinical outcomes at 
week 6 in the PURSUIT-SC induction study. In this trial, 
an exposure–response relationship was observed in patients 
in the highest serum golimumab concentration quartiles in 
the 200/100 mg and 400/200 mg golimumab group versus 
those in lower quartiles.17 The PURSUIT-Maintenance trial 
provided additional evidence that clinical response and 
remission rates were better in patients with high golimumab 
trough levels.16 Prospective studies are needed in order to 
determine the clinical benefit of therapeutic drug monitor-
ing in UC patients receiving golimumab treatment and to 
assess the optimal therapeutic window for golimumab trough 
levels. Clinical studies with larger patient cohorts should be 
conducted in order to verify whether an association can be 
Table 2 PURSUiT-SC study results
PURSUIT-SC  
study
GLM  
200/100 mg at 
weeks 0 and 2 (%)
GLM  
400/200 mg at 
weeks 0 and 2 (%)
Placebo 
(%)
Clinical response 
at week 6
51 54.9 30.3
Clinical remission 
at week 6
17.8 17.9 6.4
Mucosal healing  
at week 6
42.3 45.1 28.7
Notes: The recent Phase iii PURSUiT clinical trials were the pivotal trials that led 
to regulatory approval of golimumab for ulcerative colitis.
Abbreviations: GLM, golimumab; PURSUiT, Program of Ulcerative Colitis Res-
earch Studies Utilizing an investigational Treatment.
Table 3 PURSUiT-Maintenance trial results
PURSUIT-Maintenance GLM  
50 mg every  
4 weeks (%)
GLM  
100 mg every  
4 weeks (%)
Placebo 
(%)
Continuous clinical response  
through week 54 (among  
induction responders)
47 49.7 31.2
Clinical remission at  
weeks 30 and 54
23.2 27.8 15.6
Mucosal healing at  
weeks 30 and 54
41.7 42.4 26.6
Notes: The recent Phase iii PURSUiT clinical trials were the pivotal trials that led 
to regulatory approval of golimumab for ulcerative colitis.
Abbreviations: GLM, golimumab; PURSUiT, Program of Ulcerative Colitis Re-
search Studies Utilizing an investigational Treatment.
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found between golimumab trough levels, clinical outcomes, 
and adverse effects.
Infliximab and adalimumab have the potential to induce 
neutralizing antidrug antibodies, which can complicate 
clinical management.22 Future research should investigate 
whether antigolimumab antibodies can be detected in patients 
receiving golimumab treatment and whether this affects 
treatment outcomes.
What is the position of golimumab 
in current UC treatment?
In most inflammatory bowel disease clinics, infliximab is 
the anti-TNF agent of choice as rescue therapy for hospital-
ized patients with severe UC. However, the question needs 
to be answered how golimumab should be positioned in 
respect of infliximab and adalimumab for the treatment of 
moderate to severe UC. Up to now, no prospective head 
to head comparison has been performed in UC between 
infliximab, adalimumab, and golimumab, although most 
clinical experience has been gained with infliximab. Based 
on indirect evidence, golimumab and adalimumab seem to 
be more or less comparable in terms of mode of delivery, 
efficacy, and safety. Infliximab leads to higher remission 
rates and mucosal healing, at least in the short term.3,4 
An advantage of golimumab over infliximab (which is 
intravenously administered) might be the subcutaneous 
route of administration. An advantage of golimumab over 
adalimumab is the 4-week dosing schedule for maintenance 
treatment compared with the 2-week dosing interval that is 
being used for adalimumab. The decision on which anti-TNF 
agent to use in daily practice for the treatment of moderate to 
severe UC will be dependent on long-term real-life results, 
center and physician’s personal experience, the pricing 
and reimbursement of the different products, and patients’ 
preferences. With time, long-term clinical efficacy and 
adverse events of the different anti-TNF agents will help to 
determine which drug will be most suitable for long-term 
care in UC patients.
Practical issues with regard  
to golimumab treatment
Recent trials showed that golimumab is effective in UC as 
remission induction and maintenance therapy.16,17 Induction 
treatment with golimumab for patients with UC consists of 
200 mg subcutaneously injected at week 0 and then 100 mg 
at week 2. The FDA advises to use 100 mg every 4 weeks 
as maintenance treatment for all patients (ie, independent 
of body weight). In contrast, the EMA advice is to use 
50 mg or 100 mg every 4 weeks in patients with a body 
weight of less than 80 kg or more than 80 kg, respectively 
(Table 4). Depending on the national guidelines, golimumab 
treatment may be intensified in cases of persistent disease 
activity or disease relapse and when the drug is well toler-
ated (eg, by increasing the dose from 50 mg to 100 mg 
every 4 weeks). Golimumab trough levels can be measured 
at certain laboratories, including the Sanquin laboratory 
in  Amsterdam, the Netherlands, where a home-based test 
has recently been developed. However, additional studies 
are required in order to determine the benefit of measuring 
golimumab trough levels in daily practice and how it should 
influence clinical management. Moreover, UC patients in 
need of golimumab should preferably receive combination 
treatment with an immunomodulator in order to reduce the 
risk of developing immunogenicity, although there are no 
data to support this yet.
Screening should take place in order to exclude active 
or latent tuberculosis prior to treatment initiation with 
golimumab.23 The recommended method to diagnose latent 
tuberculosis infection is the tuberculin skin test and inter-
feron gamma assay.24 In positively screened patients, the 
pulmonologist should be consulted and preventive treatment 
should be offered before initiating treatment with golimumab, 
according to the recommendations of the American Thoracic 
Society.25,26 Screening should take place for viral infections, 
including hepatitis B, cytomegalovirus, and, in cases of 
high-risk populations, human immunodeficiency virus.23 
The varicella zoster virus (VZV) antibody test should be 
performed when prior VZV infection is unknown. The vac-
cination status should be up to date in patients who will 
start with golimumab. Hepatitis B virus vaccination may be 
considered in seronegative patients, antiviral treatment is 
recommended in hepatitis B surface antigen-positive patients, 
Table 4 induction treatment with golimumab consists of two 
injections: 200 mg and 100 mg at week 0 and week 2, respectively
Body weight ,80 kg Body weight .80 kg
induction treatment
 200 mg at week 0 200 mg at week 0
 100 mg at week 2 100 mg at week 2
Maintenance treatment
  EMA advises 50 mg every  
4 weeks
EMA advises 100 mg every 
4 weeks
  FDA advises 100 mg every  
4 weeks
FDA advises 100 mg every 
4 weeks
Abbreviations: EMA, European Medicines Agency; FDA, US Food and Drug 
Administration.
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and VZV vaccination should be considered in patients with-
out prior VZV infection before treatment initiation with 
golimumab. In patients on golimumab, live vaccines are 
contraindicated; hence, ideally, they should be administered 
prior to starting this therapy. Vaccination with a pneumococ-
cal vaccine and annual vaccination against seasonal influenza 
are recommended, along with tetanus and meningococcus 
vaccine in the appropriate setting.27 Human papilloma virus 
vaccination is recommended in young females, depending 
on national guidelines.28 During maintenance treatment with 
golimumab, it is advised to perform routine laboratory tests 
every 4 months, including serum chemistry and hematology. 
Finally, treatment with golimumab should be reconsidered 
in cases of a malignant disease within 5 years prior to treat-
ment initiation.29
Summary and conclusions
A growing number of anti-TNF agents are entering the 
clinical arena for chronic inflammatory diseases, including 
UC.  Golimumab is the latest addition to the anti-TNF class 
of drugs and is registered for the treatment of rheumatoid 
arthritis, ankylosing spondylitis, and psoriatic arthritis. 
Based on the outcomes of two recent trials, golimumab has 
recently been approved by the FDA and EMA for the treat-
ment of moderate to severe UC for those failing conven-
tional treatment. It was shown that induction therapy with 
golimumab resulted in a significantly greater proportion 
of patients achieving clinical response, clinical remission, 
and mucosal healing at week 6 compared with placebo.17 
In addition, it was demonstrated that treatment with goli-
mumab maintained clinical responses in a significantly 
greater proportion of patients up to week 54 compared 
with placebo-treated patients.16 Based on the outcomes 
of these two trials, golimumab is likely to offer an addi-
tional choice for the treatment of moderate to severe UC. 
Induction treatment with golimumab for UC consists of 
200 mg and 100 mg subcutaneously injected at week 0 and 
week 2. The FDA advises to use 100 mg every 4 weeks 
as maintenance treatment, whereas the EMA advice is to 
administer 50 mg or 100 mg at a 4-week dosing interval 
in patients with a body weight of less than or more than 
80 kg, respectively. A possible advantage of golimumab 
compared with infliximab might be the subcutaneous route 
of administration (Table 1). An advantage of golimumab 
over adalimumab is the 4-week dosing interval. Although 
the safety profile of golimumab seems to be comparable 
with the other available TNF  inhibitors, long-term data 
in UC and other inflammatory diseases are warranted in 
order to identify potential cumulative adverse effects.
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